Clinical Trial Update: Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic study of lenalidomide (Revlimid) in patients with multiple myeloma and impaired renal function.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Multiple Myeloma, Impaired Renal Function | Phase 2 | Status: COMPLETED